Study wrapper · #181
Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
Editor's note
A systematic review of cost-effectiveness, not clinical efficacy, prepared for the American College of Physicians. It asks whether weight-management drugs deliver value for money in a US setting, using incremental cost-effectiveness ratios and GRADE certainty. The headline finding is about the weakness of the evidence: across nine included studies and 42 pairwise comparisons, none reached high certainty, and all were model-based rather than trial-based. Within six moderate-certainty studies, researchers reported that tirzepatide (and phentermine-topiramate) showed high value versus lifestyle modification, while liraglutide showed low value; semaglutide showed low value against naltrexone-bupropion and phentermine-topiramate but high value against liraglutide. These are economic-model outputs, highly sensitive to drug-price assumptions, willingness-to-pay thresholds and modelled horizons, so conclusions shift as prices move. The reviewers were explicit that poor study quality limits firm conclusions. Read this as a map of where the economic evidence is thin, not as a durable value ranking, and separate cost-effectiveness entirely from questions of clinical benefit or safety.
Plain-language abstract
This review looked at whether weight-loss medicines are worth their cost in the United States, not at how well they work medically. Researchers searched medical and economic databases up to October 2025 for independent (non-industry-funded) US cost-effectiveness studies in adults with overweight or obesity. They judged value using a standard measure that weighs extra cost against extra health gain (cost per quality-adjusted life-year), and rated how trustworthy the evidence was. Only nine studies qualified, and all were based on computer models rather than direct trial costs. None of the 42 drug-to-drug comparisons reached high confidence. Among the six moderately trustworthy studies, tirzepatide and phentermine-topiramate looked like good value compared with lifestyle changes alone, while liraglutide looked like poor value. Semaglutide looked like poor value against two other drug combinations but good value compared with liraglutide. The authors stressed that most studies were low quality or incompletely reported, so firm conclusions are limited. Because these are cost models, results depend heavily on drug prices and assumptions and can change over time.